title: [Usefulness of initial chemoendocrine therapy for advanced prostate cancer].
abstract: The 5 year cancer specific survival rate of advanced prostate cancer, especially in metastatic cancer is less than 40%. Recently, maximum androgen blockade showed some beneficial effects in cases of minor disease but no additional usefulness in major cases. The treatment modality referred to as initial chemoendocrine, used to treat prostate cancer, seems to be a reasonable method because prostate cancer cells contain heterogeneity. This procedure means that the endocrine treatment is best suited to treat hormone sensitive cells, whereas chemotherapy is more appropriately used as a firstline therapy for hormone insensitive cells. We reported that the initial chemoendocrine method showed superiority in the 5 year cancer specific survival category than in the endocrine therapy analyzing non-randomized trials. From that stage on we reviewed the beneficial point of the treatment, and are now trying randomized control studies.
authors.affiliation: Department of Urology, Nagasaki University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Kanetake
authors.forename: T
authors.initials: T
authors.lastname: Igawa
authors.forename: H
authors.initials: H
authors.lastname: Sakai
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents